Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: But within the holding pattern there is a dramatic rise in "extreme" obesity among adults and children. The annual "F as in Fat" report from the Trust for America's Health and the Robert Wood Johnson Foundation found that the proportion of adults who are extremely obese - at least 100 pounds (45.4 kilograms) overweight - has climbed over the last three decades from 1.4 percent in the late 1970s to 6.3 percent in 2009-2010. That is about a 350 percent increase, researchers for the health nonprofit groups said. About 5 percent of children and teenagers are also now severely obese, they added. Rates of extreme obesity were nearly twice as high for women as for men, and were also particularly high for Hispanic boys and black girls. "As long as we continue to see those increases in extreme obesity, I think we need to be worried," Trust for America's Health Executive Director Jeffrey Levi told Reuters. Overall, the report found obesity rates stabilizing across the United States, though at historically high levels with nearly 36 percent of U.S. adults obese as of 2010. Only one state, Arkansas, had an increase in obesity levels. The findings follow this month's announcement that the obesity rate among low-income children between the ages of 2 and 4 dropped slightly, after 30 years of increases. "After decades of bad news, we're finally seeing signs of progress," researchers for the two health groups wrote in Friday's report that said government efforts to encourage healthier diets and more exercise were paying off. "I'm delighted but not surprised," said Kelly Brownell, dean of Sanford School of Public Policy at Duke University. "The collective effect is having an impact and turning things around ... We've managed the plateau, we may remain there. We will have to do more to achieve a downturn." The analysis, based on data from the Centers for Disease Control and Prevention, underscored America's continuing battle with weight. Obesity rates were highest in the South and Midwest in states including Louisiana, Mississippi and Oklahoma. In addition to geographic differences, rates were higher for people with less education and lower incomes, it found. Rates for those ages 45 to 64, the bulk of the so-called Baby Boomer generation, were also a concern as their obesity rates were 30 percent or higher in 41 states. In Alabama and Louisiana, their rate reached 40 percent. Increasingly heavy men also narrowed the obesity gender gap. "Ten years ago, the obesity rate for women was significantly higher than the rate for men," 33.4 percent compared to 27.5 percent, researchers wrote. Now, their "rates are essentially the same" at nearly 36 percent, they said. Health experts agreed with the report's conclusion that various government programs making school lunches healthier, mandating calorie counts on menus, discouraging soda consumption, integrating physical activity into the daily life and other weight-conscious changes were adding up to widespread behavior changes. The report recommended strengthening such programs. It said food and beverage companies should market only their healthiest products to children, the nation's transportation plans should encourage walking and biking, and everyone should be able to buy healthy, affordable foods close to home. Obesity is commonly measured by body mass index (BMI), a measure of one's height to weight. A BMI score of 30 or more is defined as obese, while extreme obesity is a score of 40 or higher. A score of 25 to 29 is considered overweight. Claim: U.S. obesity leveling off, but at high rate: report.

Answer: Obesity levels among adults appear to be holding steady across the United States, adding to recent evidence that the growth rate for U.S. waistlines is slowing, according to an analysis released on Friday.

Question: Paragraph: Pfizer shares were up nearly 4 percent on positive findings for the oral treatment, called palbociclib, one of the company's most important experimental drugs that some analysts believe could eventually claim annual sales of more than $5 billion, if approved. The trial tested the pill in post-menopausal patients with locally advanced or newly diagnosed breast cancer that had spread to other parts of the body. "We are delighted with the final data," Pfizer said in a release, adding the company will discuss the successful data on progression-free survival with the U.S. Food and Drug Administration "to determine next steps" for palbociclib. A secondary goal of the study is to determine whether palbociclib can prolong overall survival. But Pfizer spokeswoman Sally Beatty said the company does not yet have such data, because it takes longer periods to follow patients and gauge survival trends. Although Pfizer is conducting two larger late-stage trials of palbociclib, ISI Group analyst Mark Schoenebaum noted the company has previously said it might discuss with the FDA the potential to seek approval of the medicine based upon mid-stage trial data, if the data warranted. Palbociclib, which blocks enzymes known as cyclin-dependent kinases (CDKs) 4 and 6, was taken in combination with a standard treatment called letrozole among women who were estrogen receptor positive - meaning tumors grow in response to estrogen - and HER2-negative, meaning that the HER2 protein is not causing the cancer. Such patients make up about 60 percent of advanced breast cancer cases. Letrozole is the chemical name of Femara, a Novartis AG drug that belongs to a class of treatments called aromatase inhibitors that block production of estrogen. Pfizer on Monday did not present detailed data from the trial results, saying they would be presented at a scientific meeting in San Diego in April. The success of the trial, called Paloma-1, follows highly favorable interim data that Pfizer unveiled in December 2012. At that point in the study, those taking both palbociclib and letrozole went an average of 26.1 months before tumors worsened. That compared with 7.5 months for those taking letrozole, but not palbociclib. The 18.6-month difference was considered statistically significant. Side effects from palbociclib were similar to those previously reported, Pfizer said on Monday. The earlier interim results had shown that patients taking the drug combination experienced anemia, fatigue and neutropenia - a decline in white blood cells called neutrophils that can put patients at higher risk of infection. Palbociclib was designated a "breakthrough" drug by the FDA last April based on initial data from the trial. The FDA grants "breakthrough" status to drugs that may offer substantial improvement over existing treatments for serious or life-threatening diseases. The status helps to speed up the approval process. Pfizer has started two late-stage trials of the drug - Paloma-2 and Paloma-3 - in patients with advanced breast cancer. Paloma-2 will test the same drug combination, palbociclib and letrozole, as an initial treatment for breast cancer. Paloma-3 will evaluate palbociclib in combination with another hormone therapy, fulvestrant, in women whose cancer has progressed after hormonal therapy. The drug, sold under the brand name Faslodex by AstraZeneca Plc, is called an estrogen receptor antagonist. Companies trying to develop treatments similar to palbociclib include Novartis and Eli Lilly & Co. Breast cancer killed more than 508,000 women worldwide in 2011, according to the World Health Organization. Pfizer shares were up 3.7 percent at $31.53 on Monday morning on the New York Stock Exchange. Claim: Pfizer breast cancer drug succeeds in mid-stage trial.

Answer: Pfizer Inc's experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study's primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.

Question: Paragraph: China has been investigating 17 deaths following inoculation with a hepatitis B vaccine, made by Shenzhen-based BioKangtai, from December 13 and 31. The news alarmed many Chinese Internet users, who called on the government to make more information public. Many Chinese people are suspicious that the government tries to cover up bad news about health problems, despite assurances of transparency. In 2003, the government initially tried to cover-up the outbreak of the SARS virus. Nine of the cases have nothing to do with the vaccines, state news agency Xinhua cited the director of the disease control bureau of the National Health and Family Planning Commission, Yu Jingjin, as saying at a press conference. A preliminary analysis of the eight other cases have also found no link between the deaths and the vaccines, but the cause of the deaths will be confirmed only after autopsies, Yu said. Li Guoqing of the China Food and Drug Administration said at a press conference that no problems had been found with BioKangtai vaccines in production practices or product quality, according to Xinhua. BioKangtai said in a statement in December that it rigorously followed safety rules but that they were testing the batches suspected of causing the deaths. China has been beset by a series of product safety scandals over the past few years. At least six children died in 2008 after drinking milk contaminated by the industrial chemical melamine, and there have also been reports of children dying or becoming seriously ill from faulty encephalitis, hepatitis B and rabies vaccines. Claim: China says child deaths not linked to hepatitis vaccine.

Answer:
Chinese health authorities said they have found no link between a hepatitis B vaccine and the deaths of nine children who had received those shots, state media said on Friday.